Fractyl Health (GUTS) Cash from Operations (2023 - 2026)
Fractyl Health (GUTS) reported Cash from Operations of 22477000.0 for Q1 2026, up 10.38% year-on-year from 20364173.37 in Q1 2025, and down 5.35% quarter-over-quarter from 21336000.0 in Q4 2025.
Fractyl Health (GUTS) has 4 years of Cash from Operations data on file, last reported at 22477000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 10.38% year-over-year to 22477000.0; the trailing twelve-month figure through Mar 2026 stood at 87726000.0 (down 11.2% YoY), and the FY2025 full-year result was 90328000.0, down 37.86% from the prior year.
- Cash from Operations for Q1 2026 stood at 22477000.0, down from 21336000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9550000.0 in Q1 2023 and bottomed at 25079000.0 in Q1 2025.
- A 4-year average of 17011461.54 and a median of 18039000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 114.15% in 2025 and climbed 10.38% in 2026, its largest moves.
- Tracing GUTS's Cash from Operations over 4 years: stood at 10599000.0 in 2023, then tumbled by 60.71% to 17034000.0 in 2024, then decreased by 25.26% to 21336000.0 in 2025, then slipped by 5.35% to 22477000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 22477000.0, 21336000.0, and 22714000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.08 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | -22.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.48 Mn |
| Mar 31, 2026 | -22.48 Mn |
| Dec 31, 2025 | -21.34 Mn |
| Dec 31, 2025 | -21.34 Mn |
| Sep 30, 2025 | -22.71 Mn |
| Sep 30, 2025 | -22.71 Mn |
| Jun 30, 2025 | -21.20 Mn |
| Jun 30, 2025 | -21.20 Mn |
| Mar 31, 2025 | -25.08 Mn |
| Mar 31, 2025 | -25.08 Mn |
| Dec 31, 2024 | -17.03 Mn |
| Dec 31, 2024 | -17.03 Mn |
| Sep 30, 2024 | -18.04 Mn |
| Sep 30, 2024 | -18.04 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Mar 31, 2024 | -11.71 Mn |
| Mar 31, 2024 | -11.71 Mn |
| Dec 31, 2023 | -10.60 Mn |
| Dec 31, 2023 | -10.60 Mn |
| Sep 30, 2023 | -11.02 Mn |
| Sep 30, 2023 | -11.02 Mn |
| Jun 30, 2023 | -11.66 Mn |
| Jun 30, 2023 | -11.66 Mn |
| Mar 31, 2023 | -9.55 Mn |
| Mar 31, 2023 | -9.55 Mn |